Showing results (161-170 of 200) with videos related to
Sort By:
Pageof 20
Molecular Pharmacology|September 1, 1986
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptorsG J Kilpatrick, N el Tayar, H Van de Waterbeemd, et al.The Biochemical Journal|March 1, 1995
Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarityS Urien, Y Giroud, R S Tsai, et al.Pharmaceutical Research|May 1, 1997
Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain deliveryP Jolliet, N Simon, F Brée, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 23, 2006
Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platformsS Ekins, A Bugrim, L Brovold, et al.Bioorganic & Medicinal Chemistry|November 1, 1995
Structure-affinity relationships of baclofen and 3-heteroaromatic analoguesB Pirard, P A Carrupt, B Testa, et al.The Journal of Pharmacy and Pharmacology|June 1, 1983
Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the ratS Fleminger, H van de Waterbeemd, N M Rupniak, et al.Journal of Medicinal Chemistry|January 1, 1989
Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonistS Collin, G Evrard, D P Vercauteren, et al.Arzneimittel-Forschung|August 1, 1986
Affinity of pyridylalkylamines for nicotinic, muscarinic and histaminic recognition sites in brain tissue preparationsC Repond, J A Pratt, I P Stolerman, et al.Clinical Neuropharmacology|January 1, 1984
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's diseaseD R Cooper, C Marrel, B Testa, et al.The Journal of Pharmacy and Pharmacology|October 1, 1995
Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonismM Brunner-Guenat, P A Carrupt, G Lisa, et al.Pageof 20